WO2005037816A1 - Use of 8-prenylnaringenin for hormone replacement therapy - Google Patents
Use of 8-prenylnaringenin for hormone replacement therapy Download PDFInfo
- Publication number
- WO2005037816A1 WO2005037816A1 PCT/EP2004/011466 EP2004011466W WO2005037816A1 WO 2005037816 A1 WO2005037816 A1 WO 2005037816A1 EP 2004011466 W EP2004011466 W EP 2004011466W WO 2005037816 A1 WO2005037816 A1 WO 2005037816A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prenylnaringenin
- estradiol
- bone
- treatment
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Definitions
- This invention is directed to a production method of 8-Prenylnaringenin, the preparation produced by this method and its use for the production of a medicament.
- Hormone replacement therapy is used for the treatment of menopausal symptoms (short term) and for the prevention or treatment of hormone dependent osteoporosis (short and long term).
- the hormones may be estradiol, estrone, estriol, ethinyl estradiol or conjugated estrogens. All these estrogens are effective in the treatment of menopausal symptoms and the prevention of osteoporosis but also exhibit a non-dissociated proliferative effect on uterine tissue. This proliferation is associated with increased risk for endometriosis and endometrial cancer and lead to vaginal bleedings as a progestin is necessary from time to time to counteract the estrogenic effects on the uterus.
- estrogens which can treat menopausal symptoms and prevent or treat bone loss but only exert minimal or very low proliferative effects in the uterus.
- Continous treatment with such estrogens would not need a counteracting progestin at the level of uterine tissue.
- Some synthetic antiestrogens e.g. Tamoxifen and Raloxifen, have been synthesized which show a certain tissue selectivity (Evans ans Turner, Bone 17, 181S-190S, 19995). Also plant secondary metabolites occurring compounds were identified which show some estrogenic activity e.g. isoflavones, lignans and others.
- phyto-estrogens are, however, very weak estrogens and rather high daily doses seem to be required for clinical effects.
- the phyto-estrogen 8-Prenylnaringenin derived from the cones of hop (Humulus lupulus) was reported to have a pronounced estrogenic activity which is at least one order of magnitude higher than that of the isoflavone genistein.
- 8-Prenylnaringenin is the most potent phyto-estrogen known, this compound clearly is a good candidate for the preparation. It was, however, reported that 8- Prenylnaringenin did not show the desired tissue selectivity but has a significant effect on uterus growth at the bone loss protective dose in an animal study (Miyamoto et al 1998, Planta Medica 64, 516-519). According to these results this compound would not be chosen as the desired drug candidate.
- an animal study performed with a synthetic relatively pure 8- Prenylnaringenin preparation revealed that 8-Prenylnaringenin exerts selective effects on bone and uterus. While it prevents bone loss in a dose dependent manner, it has only a minimal and dose independent effect on uterus growth and endometrial stimulation.
- the effect of said preparation on uterus proliferation is less than 1/5 and probably 1/10 of that of estradiol wherein doses of 8-Prenylnaringenin and estradiol are compared which are equi-effective on protection of bone loss.
- 8-Prenylnaringenin (5,7-Dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)- chroman-4-on) has the following structure:
- the 4-hydroxyphenyl group may either be in the 2S(-) or the 2R (+) position. Either one of the enantiomers or the racemate may be used.
- the effect on uterus proliferation and the protection of bone loss may be measured in rats as described in example 2 (uterus weight, histology of endometrium and bone mineral density measurement).
- the 8-Prenylnaringenin preparation is synthesized by a method which is based on the method described by Gester et al (2001, Tetrahedron 57, 10115-1018) but includes several improvements.
- One embodiment of this invention is therefore a method to synthesize 8-Prenylnaringenin comprising the steps: a. diacetylation of naringenin, crystallization of product b. prenylation using tributylphosphine and diisopropylazodicarboxylate, crystallization of product c. rearrangement of prenyl side chain using Europium(lll)-fod as catalyst, product as residue after destination of solvent and d. solvolysis using K 2 CO 3 in methanol/H 2 ⁇ , product by extraction and various washing procedures
- the invention also relates to the 8-Prenylnaringenin preparation produced by the method of this invention.
- This preparation is at least 95% pure. The purity may be determined by HPLC.
- a further embodiment of this invention is the use of 8-Prenylnaringenin for the production of a medicament for the prevention and treatment of osteoporosis and of peri- and postmenopausal symptoms in women wherein the 8- Prenylnaringenin preparation used for the production is at least 95% pure.
- This invention also relates to the use of the 8-Prenylnaringenin preparation synthesized by the method of this invention for the production of a medicament for the prevention and treatment of osteoporosis and of peri- and postmenopausal symptoms in women.
- Peri- and postmenopausal symptoms are for example hot flushes, mood changes, night sweats and vaginal dryness.
- Administration of the medicament of the invention can be carried out via any of the accepted modes of administration or agents for serving similar utilities.
- administration can be, for example, orally, nasally, parenterally, topically, transdermally, or rectally, sublingually, intramuscular, subcutaneously, or intravenously in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
- compositions will include a conventional pharmaceutical carrier or excipient and 8-Prenylnaringenin as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.
- the pharmaceutically acceptable compositions will contain about 1 % to about 99% by weight of 8-Prenylnaringenin and 99% to 1 % by weight of one or more suitable pharmaceutical excipient(s).
- the composition will be about 5% to 75% by weight of 8-Prenylnaringenin, with the rest being suitable pharmaceutical excipients.
- the preferred route of administration is oral, using a convenient daily dosage regimen which can be adjusted according to the degree of severity of the disease-state to be treated.
- a pharmaceutically acceptable composition containing 8-Prenylnaringenin is formed by the incorporation of any of the normally employed excipients.
- excipients include non-toxic and chemically compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers, and the like, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, cyclodextrin, propyl gallate, and the like.
- Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.
- compositions will take the form of capsule, caplet or tablet and therefore will also contain a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as croscarmellose sodium or derivatives thereof; a lubricant such as magnesium stearate and the like; and a binder such as a starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives, and the like.
- a diluent such as lactose, sucrose, dicalcium phosphate, and the like
- a disintegrant such as croscarmellose sodium or derivatives thereof
- a lubricant such as magnesium stearate and the like
- a binder such as a starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose ether derivatives, and the like.
- 8-Prenylnaringenin may also be formulated into a suppository using, for example, about 0.5% to about 50% active ingredient disposed in a carrier that slowly dissolves within the body, e.g., polyoxyethylene glycols and polyethylene glycols (PEG), e.g., PEG 1000 (96%) and PEG 4000 (4%), and propylene glycol.
- a carrier that slowly dissolves within the body
- PEG polyoxyethylene glycols and polyethylene glycols
- Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., 8-Prenylnaringenin (about 0.5% to about 20%), and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, aqueous cyclodextrin, glycerol, ethanol and the like, to thereby form a solution or suspension.
- a carrier such as, for example, water, saline, aqueous dextrose, aqueous cyclodextrin, glycerol, ethanol and the like, to thereby form a solution or suspension.
- a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.
- composition to be administered will, in any event, contain a therapeutically effective amount 8-Prenylnaringenin for prevention and treatment of bone loss or of peri-and postmenopausal symptoms in women.
- 8-Prenylnaringenin is administered in a therapeutically effective amount which will vary depending upon a variety of factors including the age, body weight, general health, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy.
- a therapeutically effective daily dose is from about 0.5 to about 25.0 mg/kg of body weight per day 8-Prenylnaringenin preferably, from about 1 mg to about 10 mg/kg of body weight per day; and most preferably, from about 2 mg to about 5 mg/kg of body weight per day.
- Example 1 Method to synthesize 8-Prenylnaringenin
- Step 1 Acetylation of Naringenin
- naringenin available as bulk ware from various suppliers
- 200 g pyridine analytical grade
- 75 g acetic anhydride analytical grade
- the wet product is then washed with 320 ml of 0.1 N HCI and icecold water.
- the water-wet product is then boiled with 350 ml methanol and filtered twice and finally washed with 50 ml of methanol.
- the product is dried in vacuo at 40 °C over night.
- the product is pure by > 82.5 %.
- the yield is about 107 g of diacetylated product (I).
- the raw product is then stirred with 250 ml dichlormethane, filtered and again washed with 250 ml dichlormethane and dried at 40 °C.
- the raw product is then dissolved in 250 ml tert. Butylmethylether or another suitable solvent, separated from insolubles by filtration and evaporated. Residues are suspended in a small amount of dichlormethane, filtrated and the filtrate dried in vacuo at 40 °C over night. Yield is 15.9 g slightly yellowish powder with a purity of > 95 %.
- Groups 3-6 were given 17 ⁇ -estradiol (Sigma) 0.2, 0.4, 1.2 and 4.0 ⁇ g/0.5ml/kg in vehicle B/R, respectively.
- Group 7 given 17 ⁇ -estradiol (Sigma) 1.2 ⁇ g/0.5ml/kg in vehicle ethanol/arachis oil (E/A) and group 8 was administered 17 ⁇ -estradiol hemihydrate (Schering AG, Berlin) 1.2 ⁇ g/0.5mg/kg in vehicle benzyl alcohol/sesame oil (BAS/S). Treatments started on the day following surgical operation and continued for 4 weeks. At the end of the study, ex vivo BMD of proximal tibia was measured and serum estradiol was determined. In addition, uterus was weighed.
- the optimal protective subcutaneous dose of 17 ⁇ -estradiol seemed to be 4.0 ⁇ g/kg/d when administered five times a week for four weeks. This dose prevented the OVX-induced decrease in total and trabecular bone mineral density of proximal tibia and it also prevented the decrease in relative uterine weight and maintained it on the level of the SHAM vehicle group. Table 1
- the aim of the study was to examine bone and uterine effects of a 4-week treatment with 2S(-) 8-Prenylnaringenin (8-PN) in 3-month-old ovariectomized rats.
- 2S(-) 8-PN at the dose levels of 0.67 mg/kg, 1 ,77 mg/kg and 18 mg/kg was administered subcutaneously (s.c), once a day, seven times a week.
- s.c subcutaneously
- BMD bone mineral density
- the mean body weight of the animals was 271 g (SD 9, SE 2) before operation.
- Treatments with the vehicle or test substance started on the day following operation.
- the animals in the SHAM group received the vehicle, 30% hydroxypropyl- ⁇ -cyclodextrin s.c, and in the OVX groups either the vehicle or 2S(-) 8-PN at nominal doses of 0.67 mg/kg/d, 1.77 mg/kg/d or 18 mg/kg/d s.c.
- Treatments continued for 4 weeks; the dosing frequency was seven times a week.
- the animals were sacrificed one day after the last dosing.
- left tibiae were excised for ex Vo BMD measurement (pQCT) at proximal tibia and uteri were excised for the determination of absolute and relative weights.
- samples for the determination of 2S(-)8- Prenylnaringenin concentration were taken from all dosing solutions on the day when they were prepared and on the last day of use.
- the data of body weights, relative uterine weights and BMD were analyzed with one-way analysis of variance.
- Bone mineral density measurement was carried out by pQCT (XCT-960A, Stratec, Germany). The bone specimens were thawed before measurement. Six 1 mm-thick sections of the proximal tibia (2 mm below the epiphyseal growth plate) were scanned at 0.5 mm intervals using a voxel size of 0.148 mm. Total and trabecular BMD (mg/cm ) were measured. After bone densitometry, the specimens were wrapped back to saline saturated gauzes and stored at -20°C.
- Relative uterine weight was calculated as percentage of body weight
- a post-study histological examination was performed.
- the formalin fixed uteri were embedded in paraffin, cut into 5 ⁇ m transverse sections and were stained with haematoxylin eosin. The sections were then evaluated quantitatively for luminal epithelium cell height.
- the aim of the study was to directly compare the effects of Prenylnaringenin (racemate) and 2S(-) 8-Prenylnaringenin to the effects of estradiol hemihydrate on bone mineral density and uterine weight on 3-month-old ovariectomized rats using identical formulations.
- the effects of estradiolhemihydrate in two vehicles were examined for influence of formulations.
- the substances were administered subcutaneously(s.c) seven days a week beginning the day after ovariectomy. At the end of the study, uterine weight and bone mineral density (BMD) of tibia were measured.
- BMD bone mineral density
- Groups 3 and 4 were administered 4 ⁇ g/kg/d of estradiol hemihydrate in vehicle benzyl benzoate/ricinus oil (B/R) and in vehicle HP- ⁇ -CD, respectively.
- Groups 5 and 6 were given 20 mg/kg/d of 2S(-)8- Prenylnaringenin and racemic 8-Prenylnaringenin, respectively, both in vehicle HP- ⁇ -CD.
- left tibiae were excised for the ex Vo BMD substance concentrations were taken from all dosing solutions on the first and last day of use.
- the data of body weights, relative uterine weights and BMD were analyzed with one-way analysis of variance as described in example 2.
- Vehicle 1 (used in the groups 1 and 2): 30% hydroxypropyl- ⁇ -cyclodextrin and 0.3% NaCI (w/v), 5% ethanol (v/v) in Aqua sterilisata, pH 7.4.
- Vehicle 2 (used when preparing dosing solutions of the groups 4, 5 and 6): 30% hydroxypropyl- ⁇ -cyclodextrin and 0.3% NaCI (w/v) in Aqua sterilisata, pH 7.4.
- Vehicle 3 (used when preparing a dosing solution of the group 3): benzyl benzoate / ricinus oil (B/R) 1+4, v/v.
- Table 8 Trabecular density at left proximal tibia (mg/cm3).
- Estrogenic activity of the compound 2S(-)-8-prenylnaringenin (2S(-)-8-PN) in the estrogen reporter mouse ERE-Luc model (Ciana et al. Molecular Endocrinology 15: 1014, 2001)
- mice were injected intraperitoneally (i.p.) with 250 ⁇ l of an oily solution containing the following compounds: 1.
- Experimental group 1 vehicle 2.
- Experimental group 2 17 ⁇ -estradiol at 1.5 ⁇ g/kg 3.
- Experimental group 3 2S(-)-8-PN at 30 mg/kg 4.
- Experimental group 4 raloxifen at 5 ⁇ g/kg 5.
- Experimental group 5 genistein at 30 mg/kg.
- the treatment was carried out in experimental groups of three mice each and repeated three times (therefore numbers reflect the average of duplicate determinations on a total of 9 animals).
- mice Six hours after the injection, mice were sacrificed by cervical dislocation and organs were dissected and frozen on dry ice. The following organs were analyzed for lucifererase activity by enzymatic assay: prostate, liver, bone, brain. Results
- Fig.1 shows the trabecular bone mineral density (grey columns) and the relative uterine weight (black square) of rats which were either sham-operated and treated with vehicle (30% hydroxypropyl- ⁇ -cyclodextrin) or ovariectomized (ovx) and treated with the vehicle or 0.67 mg/kg, 1.77 mg/kg or 18 mg/kg 8- Prenylnaringenin.
- Fig. 2 shows the trabecular bone mineral density (grey columns) and the relative uterine weight (black square) of rats treated as described in example 3.
- 8-PN designates 8-Prenylnaringenin and Estr. designates estradiol hemihydrate.
- Fig. 3 shows the respective heights of luminal epithelium at nominal doses of 1 , 3, and 30 mg/kg 2S(-)8PN.
- Fig. 4 shows the respective heights of luminal epithelium of rats treated as described in example 3.
- Fig. 5 shows a comparison of 2S(-)8Prenylnaringenin and 2R(+)8Prenylnaringenin. Shown are the heights of luminal epithelium of rats treated with 0,015 mg/kg estradiol hemihydrate, 3/10/30 mg/kg 2S(-)8PN or 3/10/30 mg/kg 2R(+)8PN.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006530149A JP2007507462A (en) | 2003-10-07 | 2004-10-06 | Use of 8-prenylnaringenin in hormone replacement therapy |
EP04765949A EP1670777A1 (en) | 2003-10-07 | 2004-10-06 | Use of 8-prenylnaringenin for hormone replacement therapy |
US10/575,391 US20070276032A1 (en) | 2003-10-07 | 2004-10-06 | Use of 8-Prenylnaringenin for Hormone Replacement Therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03090335.5 | 2003-10-07 | ||
EP03090335A EP1524269A1 (en) | 2003-10-07 | 2003-10-07 | Use of 8-Prenylnaringenin for hormone replacement therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005037816A1 true WO2005037816A1 (en) | 2005-04-28 |
Family
ID=34354536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/011466 WO2005037816A1 (en) | 2003-10-07 | 2004-10-06 | Use of 8-prenylnaringenin for hormone replacement therapy |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070276032A1 (en) |
EP (2) | EP1524269A1 (en) |
JP (1) | JP2007507462A (en) |
WO (1) | WO2005037816A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006032500B3 (en) * | 2006-07-06 | 2007-07-12 | Technische Universität Dresden | Preparation of (2S)- and (2R)-8-prenylnaringenin, used in e.g. pharmaceuticals, comprises reducing racemic mixture of 8-prenylnarignenin derivative with formic acid and base, separating non-transferred enantiomer and splitting acyl residue |
EP1958628A1 (en) * | 2007-02-16 | 2008-08-20 | KAIROSmed GmbH | Combination of immediately liberated drospirenone with a modified releasing formulation containing 8-prenylnaringenin for use in oral contraception and hormone replacement therapy |
WO2021089840A1 (en) | 2019-11-08 | 2021-05-14 | Mrm Health N.V. | Fermentation method for the production of phytoestrogens |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1698332A1 (en) * | 2005-03-02 | 2006-09-06 | KAIROSmed GmbH | Oral modified release formulations containing 8-Prenylnaringenin for continuous estrogen support |
EP1861089A1 (en) * | 2005-03-02 | 2007-12-05 | KAIROSmed GmbH | Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support |
EP1902711A1 (en) * | 2006-09-20 | 2008-03-26 | KAIROSmed GmbH | Oral modified release formulations containing Drospirenon and 8-Prenylnaringenin for use in Hormone Replacement Therapy (HRT) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08165238A (en) * | 1994-12-12 | 1996-06-25 | Sankyo Co Ltd | Agent having estrogen-like activity |
DE10139479A1 (en) * | 2001-08-10 | 2003-02-27 | Schwabe Willmar Gmbh & Co | Hop extracts, process for their preparation and use |
-
2003
- 2003-10-07 EP EP03090335A patent/EP1524269A1/en not_active Withdrawn
-
2004
- 2004-10-06 WO PCT/EP2004/011466 patent/WO2005037816A1/en active Application Filing
- 2004-10-06 EP EP04765949A patent/EP1670777A1/en not_active Withdrawn
- 2004-10-06 US US10/575,391 patent/US20070276032A1/en not_active Abandoned
- 2004-10-06 JP JP2006530149A patent/JP2007507462A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08165238A (en) * | 1994-12-12 | 1996-06-25 | Sankyo Co Ltd | Agent having estrogen-like activity |
DE10139479A1 (en) * | 2001-08-10 | 2003-02-27 | Schwabe Willmar Gmbh & Co | Hop extracts, process for their preparation and use |
Non-Patent Citations (4)
Title |
---|
GESTER S ET AL: "an efficient synthesis of the potent phytoestrogens 8-prenylnaringenin and 6-(1,1-dimethylallyl)naringenin by europium(III)-catalyzed Claisen rearrangement", TETRAHEDRON, vol. 57, 2001, pages 1015 - 1018, XP002267058 * |
MIYAMOTO M ET AL: "Prenylflavonoids: A new class of non-steroidal phytoestrogen (part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism", PLANTA MEDICA, vol. 64, 1998, NEW YORK, pages 516 - 519, XP009023991 * |
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 10 31 October 1996 (1996-10-31) * |
ZIERAU O ET AL: "Estrogenic activity of the phytoestrogens Naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin", PLANTA MEDICA, vol. 68, 2002, pages 449 - 451, XP009023992 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006032500B3 (en) * | 2006-07-06 | 2007-07-12 | Technische Universität Dresden | Preparation of (2S)- and (2R)-8-prenylnaringenin, used in e.g. pharmaceuticals, comprises reducing racemic mixture of 8-prenylnarignenin derivative with formic acid and base, separating non-transferred enantiomer and splitting acyl residue |
EP1958628A1 (en) * | 2007-02-16 | 2008-08-20 | KAIROSmed GmbH | Combination of immediately liberated drospirenone with a modified releasing formulation containing 8-prenylnaringenin for use in oral contraception and hormone replacement therapy |
WO2021089840A1 (en) | 2019-11-08 | 2021-05-14 | Mrm Health N.V. | Fermentation method for the production of phytoestrogens |
Also Published As
Publication number | Publication date |
---|---|
US20070276032A1 (en) | 2007-11-29 |
EP1670777A1 (en) | 2006-06-21 |
EP1524269A1 (en) | 2005-04-20 |
JP2007507462A (en) | 2007-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9561238B2 (en) | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy | |
JP4047927B2 (en) | Non-steroidal polycyclic sulfamate derivatives as estrone sulfatase inhibitors, their preparation and use | |
EP0615448B1 (en) | Sex steroid activity inhibitors | |
CA2325631A1 (en) | Therapy of estrogen-associated disorders | |
US6326366B1 (en) | Hormone replacement therapy | |
ES2218400T3 (en) | 4-FLUOROALQUIL-2H-BENZOPIRANOS WITH ANTI-ESTROGENA ACTIVITY. | |
WO1998048790A1 (en) | Use of genistein and related compounds to treat certain sex hormone related conditions | |
CZ212297A3 (en) | Use of 3,4-diphenylchromans for preparing a medicament intended for treating or prophylaxis of gynecological diseases | |
JPH11510798A (en) | Naphthyl and dihydronaphthyl intermediates, compounds, compositions and methods | |
US20070276032A1 (en) | Use of 8-Prenylnaringenin for Hormone Replacement Therapy | |
KR19990077157A (en) | Use of Centroman L-Enantiomers for the Preparation of Pharmaceutical Compositions for the Treatment or Prevention of Breast Cancer | |
CA2754748A1 (en) | Estrogenic compounds and their methods of use | |
US20010047033A1 (en) | Composition for and method of preventing or treating breast cancer | |
EP0850647B1 (en) | Application of 11-substituted steroids for the preparation of medicaments with dissociated estrogenic activity | |
EP0946585B1 (en) | Steroids substituted in position 11, method of preparation, application as medicines and pharmaceutical compositions containing them | |
JPH08165238A (en) | Agent having estrogen-like activity | |
CZ211897A3 (en) | Use of 3,4-diphenylchromans for preparing pharmaceutical preparations used for dilation of vessels | |
EP1090027B1 (en) | Novel 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same | |
EP1159963A1 (en) | Composition for and method of preventing or treating breast cancer | |
Sorbera et al. | CP-336156 | |
JPH09301856A (en) | Estrogenic agent | |
KR20010055766A (en) | Metal salts of 3-methyl-chromane or thiochromane derivative | |
US20070021624A1 (en) | Steroid sulphatase inhibitors | |
EP1281710A1 (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
AU4086900A (en) | Composition for and method of preventing or treating breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004765949 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006530149 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004765949 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10575391 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10575391 Country of ref document: US |